Innovent Biologics Inc. has announced the successful dosing of the first participant in the seventh Phase 3 clinical trial (GLORY-OSA) of mazdutide in China. Mazdutide is a dual glucagon $(GCG.UK)$ and glucagon-like peptide-1 (GLP-1) receptor agonist intended for Chinese participants with moderate-to-severe obstructive sleep apnea (OSA) and obesity. This trial aims to further explore the potential of mazdutide in managing obesity and a range of metabolic syndromes. Previous studies have shown promising results, with a Phase 2 study indicating an 18.6% weight loss compared to placebo. The results of the GLORY-OSA study are expected to be presented in the future, as the study progresses.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.